Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
Key Highlights
- ➤TEMPO-1 Phase 3 dosing began for 2L+ oropharyngeal cancer in September 2026
- ➤CRB-913 60 mg produced 5% mean weight loss after 12 weeks
- ➤CANYON-1 enrolled 254 obese, non-diabetic adults in a 16-week Phase 1b trial
- ➤Q3 net loss $37.8 million, versus $23.3 million in Q3 2025
- ➤Cash, equivalents and investments totaled $115.3 million, funding operations into 2028
Expert Statements
Yuval Cohen, Chief Executive Officer of Corbus Pharmaceuticals
“During the third quarter, we achieved key milestones with both clinical programs: initiating dosing in our TEMPO-1 Phase 3 study of sutantatug envedotin in oropharyngeal cancer and announcing positive topline data from our CANYON-1 Phase 1b study of CRB-913 in obesity”
Yuval Cohen, Chief Executive Officer of Corbus Pharmaceuticals
“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”
Yuval Cohen, Chief Executive Officer of Corbus Pharmaceuticals
“Based on our Phase 1/2 data, we believe that sutantatug envedotin has the potential to address the critical unmet need of patients with this difficult-to-treat, primarily HPV-driven disease.”
Yuval Cohen, Chief Executive Officer of Corbus Pharmaceuticals
“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”
Yuval Cohen, Chief Executive Officer of Corbus Pharmaceuticals
“We look forward to presenting additional data at ObesityWeek®.”
* Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer * Reported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating mean weight loss of 5% after 12 weeks at 60 mg daily dose with no plateau observed and favorable safety and tolerability * Late-breaking CANYON-1 data to be presented at ObesityWeek® 2026 on Saturday, November 15, 2026 NORWOOD, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 third quarter ended September 30, 2026.
"During the third quarter, we achieved key milestones with both clinical programs: initiating dosing in our TEMPO-1 Phase 3 study of sutantatug envedotin in oropharyngeal cancer and announcing positive topline data from our CANYON-1 Phase 1b study of CRB-913 in obesity,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy. Based on our Phase 1/2 data, we believe that sutantatug envedotin has the potential to address the critical unmet need of patients with this difficult-to-treat, primarily HPV-driven disease. For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s. We look forward to presenting additional data at ObesityWeek®.”
Get started
Create a free account to read the full story.